Agenus Profile

4.47
USD 0.14  3.23%
4.33Last Month High 4.78 
3.93Trading Day  High 4.71 

Acquisition by Tom Dechaene of 697 shares of Agenus subject to Rule 16b-3

Agenus Inc insider trading alert for grant of deferred shares by Tom Dechaene, the corporate stakeholder, on October 15, 2017. This event was filed by Agenus Inc with SEC on 2013-07-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Agenus Summary

Agenus Inc (AGEN) is traded on Nasdaq Capital Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 224 people. Agenus is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 461.9 M. Agenus Inc has 99.12 M outstanding shares of which 9.89 M shares are presently shorted by private and institutional investors with about 7.7 trading days to cover. ANTIGENICS INC currently holds about 96.77 M in cash with (82.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.97.
Check Agenus Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fisher Asset Management LlcCommon Shares192.9 K851 K
Quotient Investors LlcCommon Shares16.6 K73 K
View Agenus Diagnostics

Selected Agenus Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Agenus Against Markets

Risk Adjusted
Performance Score (0 to 100)
7 
Chance of
< 81% 
Agenus Inc., an immunooncology company, focuses on the discovery and development of treatments that engage the bodys immune system for patients suffering with cancer. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameAgenus Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationMASSACHUSETTS, U.S.A
Business Address3 Forbes Road, Lexington, MA 02421, United States
ExchangeNasdaq Capital Markets
CIK Number01098972.0
CUSIP00847G705
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.agenusbio.com
Contact Number781 674 4400
CurrencyUSD - US Dollar

Recommendations

Agenus Analyst Recommendations
Target PriceAdvice# of Analysts
6.33Buy3Odds
Agenus Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Agenus Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Agenus Earnings Estimates
Agenus Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate